OSU K12 Training Grant for Clinical Faculty Investigators

描述(由申请人提供)：本提案的目标是在基础科学和/或面向临床的翻译研究方法方面指导和有效培训教职级研究人员。为血液肿瘤学、内科肿瘤学、放射肿瘤学和外科肿瘤学的基础转化型科学家(博士、DVM和MD)和临床转化型科学家(MD和MD/PhD)的职业发展颁发这一K12奖将确保一支训练有素的个人干部队伍致力于药物开发以及癌症预防、控制和生存研究。俄亥俄州立大学综合癌症中心(OSUCCC)的这次K12更新继续了其对早期药物开发以及更大的II/III期试验的培训重点，但现在也扩展到基于先前批评的癌症预防、控制和生存研究。重点招募对常见实体肿瘤感兴趣的学者，如所建议的那样。OSUCCC显然致力于研究教育，并为有前途的初级教师提供出色的培训和指导机会。俄亥俄州立大学血液学、内科肿瘤学、放射肿瘤学和外科肿瘤学分部都有强大的团契培训计划，不断招聘新的初级教员，以促进我们癌症计划的扩展。还从其他研究金培训方案中招募人员，特别注重识别妇女、少数群体和不同族裔背景的人，以增加多样性。这笔K12助学金通过将研究教育、培训和指导扩展到对发展专注于临床研究的学术生涯感兴趣的初级教员来满足重要的需求。此外，这将是OSUCCC唯一专门致力于教师层面癌症职业发展的培训计划，因此与OSU T32专注于研究员的任何培训拨款没有重叠。这一战略将确保培训的连续性，并使个人能够成为独立的临床研究人员。基于OSUCCC的整体实力和方向，如最近同行评议的12分(例外)、OSUCCC对这项K12的财政支持、不同司和部门的财务支持以及OSU的广泛资源所表明的那样，这项K12建议旨在主要培训两类助理教授。第一组包括医学博士或博士教师(基础翻译实习生)，他们接受过出色的基础科学培训，并渴望从事与实验疗法应用研究以及癌症预防、控制和生存相关的实验室研究。第二组包括医学博士或医学博士(临床翻译实习生)，他们从事以临床为重点的与患者相关的研究 实验疗法和癌症的预防、控制或生存。为每个学员量身定做的培训计划将促进他们的成功，其中包括一项ROUST评估计划，以评估K12的成功。这一点最好的证明是所有现在和过去的K12学者仍然留在学术医学中，并作为独立的临床研究人员向前迈进。

DESCRIPTION (provided by applicant): The goal of this proposal is to mentor and effectively train faculty-level investigators in basic science and/or clinically-oriented approaches to translational research. Implementation of this K12 award for the career development of basic translational scientists (PhD, DVM, and MD) and clinical translational scientists (MD and MD/PhD) in Hematologic Oncology, Medical Oncology, Radiation Oncology and Surgical Oncology will ensure a cadre of highly-trained individuals dedicated to drug development as well as cancer prevention, control, and survivorship research. This K12 renewal from The Ohio State University Comprehensive Cancer Center (OSUCCC) continues its training focus on early drug development along with larger phase II/III trials, but now also extends to cancer prevention, control and survivorship research based on the previous critique. Focus on recruitment of scholars with interest in common solid tumors is also emphasized, as suggested. The OSUCCC is clearly dedicated to research education and providing outstanding training and mentoring opportunities to promising junior faculty. The OSU Divisions of Hematology, Medical Oncology, Radiation Oncology, and Surgical Oncology each have robust fellowship training programs that are continuously recruiting new junior faculty to facilitate expansion of our cancer program. Recruitment from other fellowship training programs also occurs, with particular focus on identification of women, minorities and people of different ethnic backgrounds to increase diversity. This K12 grant fills an important need by extending research education, training and mentoring to junior faculty interested in developing academic careers focused on clinical research. Moreover, it will be the only OSUCCC training program solely dedicated to career development in cancer at the faculty level, and therefore has no overlap with any of the OSU T32 training grants focused on fellows. This strategy will ensure continuity in training and provide individuals with the ability to become independent clinical investigators. Based upon the overall strength and direction of the OSUCCC, as demonstrated by its recent peer review score of 12 (exceptional), financial support of this K12 by OSUCCC, financial support by different Divisions and Departments, and breadth of resources available at OSU, this K12 proposal seeks to train primarily two types of assistant professors. The first group includes MD or PhD faculty (basic translational trainees) who have outstanding basic science training and desire to pursue laboratory investigation related to applied research in experimental therapeutics as well as cancer prevention, control, and survivorship. The second group includes MD or MD/PhD faculty (clinical translational trainees) who pursue patient-related research in clinically-focused experimental therapeutics and cancer prevention, control, or survivorship. Training plans tailored to each of these individual trainees will facilitate their success, with inclusion of a roust evaluation program to assess the success of the K12. This is best demonstrated by all of the current and past K12 scholars remaining in academic medicine and moving forward as independent clinical investigators.